Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. sold 9,144 shares of the stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $11.78, for a total value of $107,716.32. Following the sale, the insider now owns 3,068,072 shares of the company's stock, valued at $36,141,888.16. This represents a 0.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Saba Capital Management, L.P. also recently made the following trade(s):
- On Monday, April 14th, Saba Capital Management, L.P. sold 15,400 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $11.67, for a total transaction of $179,718.00.
- On Thursday, April 10th, Saba Capital Management, L.P. sold 30,156 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.14, for a total transaction of $335,937.84.
- On Friday, April 4th, Saba Capital Management, L.P. sold 6,889 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.57, for a total transaction of $79,705.73.
- On Wednesday, April 2nd, Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.28, for a total value of $357,372.56.
- On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.58, for a total value of $611,677.34.
- On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.01, for a total value of $428,315.22.
- On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.62, for a total transaction of $2,724.00.
- On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.75, for a total transaction of $502,370.00.
- On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.95, for a total value of $599,668.65.
- On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.03, for a total value of $25,899.38.
Abrdn Life Sciences Investors Trading Down 0.5 %
Shares of Abrdn Life Sciences Investors stock opened at $11.76 on Tuesday. The stock has a 50 day moving average price of $12.74 and a 200-day moving average price of $13.67. Abrdn Life Sciences Investors has a one year low of $10.55 and a one year high of $15.90.
Abrdn Life Sciences Investors Cuts Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Friday, February 21st were given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 15.99%. The ex-dividend date was Friday, February 21st.
Institutional Investors Weigh In On Abrdn Life Sciences Investors
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC grew its holdings in Abrdn Life Sciences Investors by 3.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 30,119 shares of the company's stock valued at $395,000 after purchasing an additional 933 shares during the last quarter. 180 Wealth Advisors LLC raised its holdings in shares of Abrdn Life Sciences Investors by 0.9% in the first quarter. 180 Wealth Advisors LLC now owns 136,122 shares of the company's stock worth $1,727,000 after buying an additional 1,247 shares during the period. Kapstone Financial Advisors LLC lifted its stake in shares of Abrdn Life Sciences Investors by 11.0% during the 4th quarter. Kapstone Financial Advisors LLC now owns 13,123 shares of the company's stock worth $185,000 after acquiring an additional 1,300 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in Abrdn Life Sciences Investors by 11.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company's stock valued at $183,000 after acquiring an additional 1,355 shares during the period. Finally, BankPlus Trust Department bought a new position in Abrdn Life Sciences Investors in the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 32.21% of the company's stock.
Abrdn Life Sciences Investors Company Profile
(
Get Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
